Canada Approves Wegovy as First Treatment to Reduce Nonfatal Heart Attack Risk on November 27, 2024

Nov 27, 2024, 06:47 PM

Canada's health regulator has granted approval for Novo Nordisk's weight loss drug, Wegovy, aimed at reducing the risk of nonfatal heart attacks or myocardial infarctions in certain adults. This marks Wegovy as the first treatment in Canada to simultaneously address obesity and the risk of heart-related conditions for adults with established cardiovascular disease. The announcement was made by the Danish drugmaker on November 27, 2024, highlighting the drug's potential in combating significant health risks associated with obesity.